Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials

By M. Lalu, L. McIntyre, C. Pugliese, D. Fergusson, B. Winston, J. Marshall, J. Granton, D. Stewart. PLoS ONE, 2012

1,058 citations recorded by the source corpus.

Background Mesenchymal stromal cells (MSCs, “adult stem cells”) have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety. Methods and Findings MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously or intra-arterially) in adult populations or mixed adult and pediatric populations were identified. Studies using differentiated MSCs or additional cell types were excluded. The primary outcome adverse events were grouped according to immediate events (acute infusional toxicity, fever), organ system complications, infection, and longer term adverse events (death, malignancy). 2347 citations were reviewed and 36 studies met inclusion criteria. A total of 1012 participants with clinical conditions of ischemic stroke, Crohn's disease, cardiomyopathy, myocardial infarction, graft versus host disease, and healthy volunteers were included. Eight studies were randomized control trials (RCTs) and enrolled 321 participants. Meta-analysis of the RCTs did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. There was a significant association between MSCs and transient fever. Conclusions Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.

Subfields: Genetics, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/199b3abda932d6e7c8f037e930d98bbeef1a049a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

T. Squillaro
G. Peluso
Jianxun Ding
Yanbo Zhang
Yu Han
U. Galderisi
Xue-zhou Li
F. Chang

Citations in the corpus

Clinical Trials with Mesenchymal Stem Cells: An Update (2016, background): “organ transplantations, to heal refractory wounds and to counteract defects in the bones and cartilage (55,63,132).”
Mesenchymal Stem Cells for Regenerative Medicine (2019, background): “Fortunately, major adverse events were rare according to clinical trials evaluation of MSC therapy [234].”